Tenaya Therapeutics (TNYA) Retained Earnings (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Retained Earnings of -$624.3 million for Q1 2026, down 15.34% year-over-year from -$737.4 million in Q1 2025, and down 3.19% quarter-over-quarter from -$605.0 million in Q4 2025.
Tenaya Therapeutics (TNYA) Retained Earnings (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$624.3 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 15.34% year-over-year to -$624.3 million; the TTM figure through Mar 2026 stood at -$624.3 million (down 15.34% YoY), while the FY2025 annual figure was -$605.0 million, down 17.61% from the prior year.
- Retained Earnings for Q1 2026 stood at -$624.3 million, down from -$605.0 million in the prior quarter.
- The five-year high for Retained Earnings was $603.1 million in Q3 2024, with the low at -$624.3 million in Q1 2026.
- The 5-year median for Retained Earnings is -$186.6 million (2022), against an average of -$101.3 million.
- Peak annual rise in Retained Earnings reached 231170.11% in 2024, while the deepest fall reached 485193.4% in 2024.
- Tenaya Therapeutics' Retained Earnings stood at -$378000.0 in 2022, then jumped by 71.96% to -$106000.0 in 2023, then slumped by 485193.4% to -$514.4 million in 2024, then fell by 17.61% to -$605.0 million in 2025, then fell by 3.19% to -$624.3 million in 2026.
- Business Quant data shows TNYA's Retained Earnings at -$624.3 million in Q1 2026, -$605.0 million in Q4 2025, and -$584.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - | 737.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 737.06 Mn |
| Mar 31, 2026 | -624.28 Mn |
| Dec 31, 2025 | -605.01 Mn |
| Sep 30, 2025 | -584.80 Mn |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | -541.28 Mn |
| Dec 31, 2024 | -514.41 Mn |
| Sep 30, 2024 | 603.09 Mn |
| Jun 30, 2024 | 599.00 Mn |
| Mar 31, 2024 | 593.80 Mn |
| Dec 31, 2023 | -106,000.00 |
| Sep 30, 2023 | -261,000.00 |
| Jun 30, 2023 | -344.20 Mn |
| Mar 31, 2023 | -310.90 Mn |
| Dec 31, 2022 | -378,000.00 |
| Sep 30, 2022 | -245.68 Mn |
| Jun 30, 2022 | 439.59 Mn |
| Mar 31, 2022 | -186.59 Mn |
| Dec 31, 2021 | -141,000.00 |
| Sep 30, 2021 | 433.11 Mn |